Deferoxamine Treatment Prevents Post-Stroke Vasoregression and Neurovascular Unit Remodeling Leading to Improved Functional Outcomes in Type 2 Male Diabetic Rats: Role of Endothelial Ferroptosis

• Published in: Translational stroke research Vol. 12; no. 4; pp. 615 - 630
• Main Authors: Abdul, Yasir, Li, Weiguo, Ward, Rebecca, Abdelsaid, Mohammed, Hafez, Sherif, Dong, Guangkuo, Jamil, Sarah, Wolf, Victoria, Johnson, Maribeth H., Fagan, Susan C., Ergul, Adviye
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.08.2021; Springer Nature B.V
• Subjects: Animals; Asymptomatic; Biomedical and Life Sciences; Biomedicine; Brain research; Cardiology; Catheters; Deferoxamine - therapeutic use; Diabetes; Diabetes Mellitus, Experimental - complications; Diabetes Mellitus, Type 2; Endothelial Cells; Ferroptosis; Glucose; Ischemia; Laboratory animals; Male; Mortality; Neurology; Neurosciences; Neurosurgery; Original Article; Rats; Stroke; Stroke - complications; Stroke - drug therapy; Surgery; Thromboembolism; Vascular Surgery; Post-stroke cognitive impairment; Iron chelation; Stroke; Ferroptosis; Hemorrhagic transformation; Diabetes; Vascularization
• ISSN: 1868-4483; 1868-601X; 1868-601X
• DOI: 10.1007/s12975-020-00844-7

It is a clinically well-established fact that patients with diabetes have very poor stroke outcomes. Yet, the underlying mechanisms remain largely unknown. Our previous studies showed that male diabetic animals show greater hemorrhagic transformation (HT), profound loss of cerebral vasculature in the recovery period, and poor sensorimotor and cognitive outcomes after ischemic stroke. This study aimed to determine the impact of iron chelation with deferoxamine (DFX) on (1) cerebral vascularization patterns and (2) functional outcomes after stroke in control and diabetic rats. After 8 weeks of type 2 diabetes induced by a combination of high-fat diet and low-dose streptozotocin, male control and diabetic animals were subjected to thromboembolic middle cerebral artery occlusion (MCAO) and randomized to vehicle, DFX, or tPA/DFX and followed for 14 days with behavioral tests. Vascular indices (vascular volume and surface area), neurovascular remodeling (AQP4 polarity), and microglia activation were measured. Brain microvascular endothelial cells (BMVEC) from control and diabetic animals were evaluated for the impact of DFX on ferroptotic cell death. DFX treatment prevented vasoregression and microglia activation while improving AQP4 polarity as well as blood-brain barrier permeability by day 14 in diabetic rats. These pathological changes were associated with improvement of functional outcomes. In control rats, DFX did not have an effect. Iron increased markers of ferroptosis and lipid reactive oxygen species (ROS) to a greater extent in BMVECs from diabetic animals, and this was prevented by DFX. These results strongly suggest that (1) HT impacts post-stroke vascularization patterns and recovery responses in diabetes, (2) treatment of bleeding with iron chelation has differential effects on outcomes in comorbid disease conditions, and (3) iron chelation and possibly inhibition of ferroptosis may provide a novel disease-modifying therapeutic strategy in the prevention of post-stroke cognitive impairment in diabetes.